Transitioning Treatment in Diabetic Retinopathy

Posttest

Question 1

Which of the following was seen in the phase 3 PANORAMA study that compared intravitreal aflibercept with sham in the treatment of patients with diabetic retinopathy (DR)?

A. Intravitreal aflibercept and sham had similar rates of >2-step improvement in DR severity score.

B. Intravitreal aflibercept and sham had similar rates of development of vision-threatening complications.

C. Patients treated with intravitreal aflibercept had significantly greater rates of ≥2-step improvement in DR severity score.

D. Patients treated with intravitreal aflibercept required monthly injections.

Question 2

Which of the following was seen in the DRCR.net Protocol S study, which compared panretinal photocoagulation (PRP) versus ranibizumab for proliferative diabetic retinopathy?

A. Patients treated with PRP had superior mean best-corrected visual acuity (BCVA) compared with those treated with ranibizumab.

B. 47% of eyes treated with ranibizumab had improved by 2 or more steps.

C. Patients treated with ranibizumab had an increased occurrence of vitrectomy.

D. Patients treated with ranibizumab had an increased risk of development of center-involving diabetic macular edema (CI-DME).

Back